| Literature DB >> 33794801 |
Peer Oscar Overgaard Stenholt1, S M Osama Bin Abdullah2, Rune Husås Sørensen2,3, Finn Erland Nielsen4,5.
Abstract
BACKGROUND: The primary objective of our study was to examine predictors for readmission in a prospective cohort of sepsis patients admitted to an emergency department (ED) and identified by the new Sepsis-3 criteria.Entities:
Keywords: Emergency department; Predictors; Readmission; Sepsis
Year: 2021 PMID: 33794801 PMCID: PMC8017866 DOI: 10.1186/s12879-021-06007-9
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Study flow chart
Baseline characteristics according to 90-day readmission in septic patients
| Readmitted | Not readmitted | Difference | |
|---|---|---|---|
| Female gender; n(%)a | 105 (44.3) | 187 (44.0) | 0.3(÷7.5–8.2) |
| Age; median years (IQR)a | 74.9 (64.7–83.9) | 74.8 (66.6–84.4) | 0.1(÷1.9–2.3) |
| Medical history | |||
| Charlson Comorbidity Score; n(%) | |||
| 0 | 46 (19.4) | 125 (29.4) | 10.0 (3.4–16.6) |
| 1–2 | 108 (45.6) | 210 (49.4) | 3.8(÷11.7–4.1) |
| 3 + b | 83 (35.0) | 90 (21.2) | 13.8 (6.6–21.0) |
| Heart failurea | 39 (16.5) | 63 (14.8) | 1.7(÷4.1–7.5) |
| Myocardial infarction/Ischemic heart diseasea | 33 (13.9) | 53 (12.5) | 1.4(÷4.0–6.8) |
| Chronic obstructive pulmonary diseasea | 64 (27.0) | 96 (22.6) | 4.4(÷2.5–11.3) |
| Malignant diseaseb,c | 47 (19.8) | 47 (11.0) | 8.8 (2.9–14.9) |
| Diabetesa,d | 55 (23.2) | 85 (20.0) | 3.2(÷3.4–9.8) |
| Kidney diseasea,e | 24 (10.1) | 33 (7.8) | 2.3(÷2.3–6.9) |
| Liver diseasea,f | 3 (1.3) | 10 (2.4) | 1.1(÷1.1–3.3) |
| Cerebrovascular diseasea,g | 49 (20.7) | 75 (17.7) | 3.0(÷3.3–9.3) |
| Hypertensiona | 89 (37.6) | 154 (36.2) | 1.4(÷6.2–9.1) |
| History of sepsis within last year before admission; n(%)b | 87 (36.7) | 106 (24.9) | 11.8 (4.4–19.2) |
| Admission | |||
| Length of stay; days (IQR)a | 7 (4–10) | 6 (3–9) | 1(÷1–0) |
| Atrial fibrillation | |||
| None, n(%)a | 175 (73.8) | 323 (76.0) | 2.2(÷9.1–4.7) |
| New-onset atrial fibrillation; n(%)a | 9 (3.8) | 23 (5.4) | 1.6(÷4.8–1.7) |
| History of atrial fibrillation; n(%)a | 53 (22.4) | 79 (18.6) | 3.8(÷2.7–10.3) |
| Severity of disease | |||
| Total SOFA score (IQR)a | 3 (2–4) | 3 (2–3) | 0 |
| Systolic blood pressure; mmHg, median (IQR)a,h | 122 (105–144) | 126 (109–147) | 3(÷1–8) |
| Systolic blood pressure < 90 mmHg, n(%)a | 13 (5.6) | 20 (4.8) | 0.8(÷2.8–4.4) |
| Respiratory rate; min−1, median (IQR)a | 20 (17–24) | 20 (18–24) | 0 |
| Heart rate; min−1, median (IQR)a | 90 (80–105) | 93 (77–109) | 2(÷2–5) |
| O2-Saturation; %, median (IQR)a | 95 (92–97) | 95 (93–97) | 0 |
| Core temperature; oCelcius, median (IQR)a,i | 37.2 (36.6–38.0) | 37.4 (36.7–38.4) | 0.2 (0–0.4) |
| Altered mental state; n (%)a | 62 (26.2) | 117 (27.5) | 1.3(÷8.3–5.7) |
| qSOFA score ≥ 2 on admission; n(%)a | 48 (20.3) | 78 (18.4) | 1.9(÷4.4–8.2) |
| SIRS criteria ≥2 on admission, n(%)a | 131 (55.3) | 263 (61.9) | 6.6(÷1.2–14.4) |
| Laboratory results | |||
| CRP; median (IQR)b | 65 (23–123) | 82 (24–160) | 10.9 (1.0–21.9) |
| White blood cell count ×109/L, median (IQR)a | 12.1 (8.9–16.1) | 11.6 (8.6–16.6) | 0.1(÷1.0–0.8) |
| Creatinine, μmol/L, median (IQR)a | 115 (80–178) | 113 (75–168) | 5.0(÷15.0–4.0) |
| Bilirubin, mmol/L, median (IQR)a | 10 (7–16) | 10 (7–18) | 1 (0–2) |
| Platelets, ×109/L, median (IQR)a | 216 (153–288) | 205 (144–283) | 10(÷26–5) |
| Lactate; mmol/L, median (IQR)a,j | 1.2 (0.8–2.0) | 1.3 (0.9–2.1) | 0.1(÷0.1–0.2) |
| Glucose, mmol/L, median (IQR)b | 6.8 (5.9–8.2) | 7.3 (6.0–8.9) | 0.4 (0.1–0.7) |
| Admission to intensive care unit, n (%)a | 24 (10.1) | 56 (13.2) | 3.1(÷8.1–1.9) |
| Vasopressor, n (%)b | 1 (0.4) | 10 (2.4) | 2.0 (0.3–3.7) |
| Mechanical ventilation, n (%)a | 8 (3.4) | 23 (5.4) | 2.0(÷1.2–5.2) |
| Dialysis, n (%)a | 1 (0.4) | 2 (0.5) | 0.1(÷1.1–0.9) |
| Positive blood cultures, n (%)a,k | 18 (12.6) | 38 (14.1) | 1.5(÷6.8–3.9) |
| Source of infection | |||
| Pulmonary, n (%)a | 137 (57.8) | 252 (59.3) | 1.5(÷9.3–6.3) |
| Urine, n (%)a | 47 (19.8) | 101 (23.8) | 4.0(÷10.5–2.5) |
| Abdominal, n (%)a | 26 (11.0) | 40 (9.4) | 1.6(÷3.3–6.5) |
| Skin, n(%)a | 19 (8.0) | 26 (6.1) | 1.9(÷2.2–6.0) |
| Endocarditis, n(%)a | 1 (0.4) | 1 (0.2) | 0.2(÷0.7–1.1) |
| Central nervous system, n (%)a | 1 (0.4) | 3 (0.7) | 0.3(÷1.4–0.8) |
| Facial/teeth, n(%)a | 1 (0.4) | 1 (0.2) | 1.9(÷2.2–6.0) |
| Devices/implants | 0 | 0 | – |
| Others, n(%)a | 3 (1.3) | 0 | 1.3(÷0.1–2.7) |
| Unknown, n(%)a | 19 (8.0) | 35 (8.2) | 0.2(÷4.5–4.1) |
| > 1 focus, n(%)a | 18 (7.6) | 33 (7.8) | 0.2(÷4.4–4.0) |
CI confidence interval, CRP C-reactive protein, IQR interquartile range, qSOFA quick Sequential Organ Failure Assessment, SIRS Systemic Inflammatory Response Syndrome, SOFA Sequential Organ Failure Assessment
aNinety-five percent CI for the median difference or 95% CI for the difference of proportions included zero
bNinety-five percent CI for the median difference or 95% CI for the difference of proportions did not include zero
cTumor without metastasis, leukemia, lymphoma or metastatic tumors
dDiabetes with or without end organ damage
eMild or severe kidney disease
fMild or severe liver disease
gHistory of cerebrovascular disease including transient ischemic attack or a condition with hemiplegia
hNine patients with missing blood pressure
iFifteen patients with missing temperature
j(131/237 and 245/425) with measurement of lactate
kA total of 413 patients with blood cultures obtained
Medical treatment on admission according to 90-day readmission in septic patients
| Medication, N(%) | Readmitted | Not readmitted | Difference |
|---|---|---|---|
| Cardiac | |||
| Beta-blockersa | 75 (31.7) | 112 (26.4) | 5.3(÷2.0–12.6) |
| Calcium antagonistsa | 42 (17.7) | 90 (21.2) | 3.5(÷9.7–2.7) |
| Digoxina | 14 (5.9) | 15 (3.5) | 2.4(÷1.1–5.9) |
| ACE-inhibitors/AII-antagonistsa | 82 (34.6) | 137 (32.2) | 2.4(÷5.1–9.9) |
| Anticoagulantsb,c | 126 (53.2) | 190 (44.7) | 8.5 (0.6–16.4) |
| Diureticsb | 126 (53.2) | 167 (39.3) | 13.9 (6.0–21.8) |
| Lipid lowering drugsa | 79 (33.3) | 119 (28.0) | 5.3(÷2.0–12.7) |
| Pulmonary | |||
| Inhalation medicationsa | 58 (24.5) | 89 (20.9) | 3.6(÷3.1–10.3) |
| Diabetes | |||
| Insulin/peroral antidiabeticsa | 42 (17.7) | 74 (17.4) | 0.3(÷5.7–6.3) |
| Psychopharmacology medicationa,d | 42 (17.7) | 75 (17.7) | 0 |
| Analgesic | |||
| Opioidsb | 51 (21.5) | 62 (14.6) | 6.9 (0.7–13.1) |
| Other analgesicsa,e | 78 (32.9) | 147 (34.4) | 1.5(÷9.0–6.0) |
ACE Angiotensin-converting enzyme (ACE) inhibitors, AII angiotensin II receptor antagonists, CI confidence interval
aNinety-five percent CI for the difference of proportions included zero
bNinety-five percent CI for the difference of proportions did not include zero
cAcetylsalicylic acid, Non-Vitamin K antagonist oral anticoagulants, Warfarine/Dicoumarol
dAntipsychotics, Lithium, antidepressants, benzodiazepines
eParacetamol, caffeine-phenazon, codeine, non-steroidal anti-inflammatory drugs, others
Unadjusted and adjusted competing-risks regression analyses of covariates and 90-day readmission among septic patients
| Unadjusted subhazard ratio | Adjusted subhazard ratio (full model)a (95% CI) | Adjusted subhazard ratio (final model) (95% CI) | |
|---|---|---|---|
| Ageb | 1.00 (0.99–1.01) | 0.99 (0.98–1.00) | – |
| Female gender | 1.02 (0.79–1.32) | 1.06 (0.81–1.38) | – |
| COPD | 1.24 (0.93–1.66) | 1.16 (0.88–1.55) | – |
| Diabetes | 1.12 (0.84–1.51) | 1.09 (0.77–1.52) | – |
| Kidney disease | 1.27 (0.83–1.94) | 1.13 (0.74–1.70) | – |
| C-reactive proteinb | 0.998 (0.997–1.000) | 1.00 (1.00–1.00) | – |
| Glucoseb | 0.99 (0.95–1.02) | 0.98 (0.94–1.02) | – |
| Anticoagulant treatment | 1.31 (1.01–1.68) | 1.21 (0.91–1.61) | – |
| Vasopressor treatment | 0.22 (0.03–1.72) | 0.19 (0.02–1.58) | – |
| Opioid treatment | 1.43 (1.05–1.94) | 1.22 (0.90–1.67) | – |
| Malignant disease | 1.70 (1.24–2.34) | 1.68 (1.20–2.33) | 1.61 (1.16–2.23) |
| Previous admitted with sepsis | 1.51 (1.17–1.97) | 1.28 (0.97–1.67) | 1.41 (1.08–1.84) |
| Treatment with diuretics | 1.53 (1.18–1.98) | 1.48 (1.12–1.95) | 1.51 (1.17–1.94) |
CI confidence interval, COPD chronic obstructive pulmonary disease
aVariables adjusted for all other variables
bIncrease of hazard ratio for one unit increase of the variable